Lisa Sevenich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lisa Sevenich has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
Katja Niesel
Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany
6 shared publicationsMichael Schulz
Institute for Tumor Biology and Experimental Therapy
4 shared publications- Michael Schulz
Institute of Neuropathology, Medical Center, University of Freiburg, Freiburg, Germany
4 shared publications Tijna Alekseeva
Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany
4 shared publicationsAylin Möckl
Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt am Main, Germany; Johannes Gutenberg-University Mainz, Mainz, Germany
3 shared publicationsFranz Rödel
Frankfurt Cancer Institute (FCI)Goethe University Frankfurt Frankfurt am Main Germany
3 shared publications
Latest Publications
- Open Access
- 20 October 2026
- Published by Elsevier in STAR Protocols
- Vol. 7 (4)
Protocol for isolation and culture establishment of adult murine neural stem cells using tissue grinder and dissociator-based mechanical dissociation
- 20 October 2026
- Published by Elsevier in STAR Protocols
- Vol. 7 (4)
Open AccessProtocol for isolation and culture establishment of adult murine neural stem cells using tissue grinder and dissociator-based mechanical dissociation
- Open Access
- 29 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9236
DNA methylation profiling identifies long-range epigenetic silencing of clustered protocadherins as a key determinant of meningioma progression
Meningioma is the most common primary brain tumour in adults. However, molecular drivers of progression occurring in a subset of meningiomas are poorly understood. We hypothesise that epigenomic variations are causal for the clinical heterogeneity of meningiomas and may be functionally relevant for disease progression. To test this hypothesis, we perform global DNA methylation profiling of a large cross-sectional cohort and a longitudinal cohort of human meningiomas. Our analysis identifies a DNA hypermethylation signature that is correlated with clinical outcomes and enables more accurate prognostication for meningiomas than previous classification systems. Analyses of longitudinal high-grade meningioma samples in comparison to clinically benign meningiomas and normal meningeal tissue show convergent contributions but differing plasticity of copy number variations and DNA hypermethylation along the trajectory of meningioma progression. Systematic analysis of DNA hypermethylation in high-grade meningiomas unravels a tumour suppressive role of clustered protocadherins by restricting β-catenin nuclear localisation, consistent with the association between nuclear β-catenin staining and meningioma progression. Together, our study provides fundamental insights into the molecular mechanisms underlying the heterogeneity of clinically benign and aggressive meningiomas and the microevolutionary adaptation during disease progression.
- 29 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9236
Open AccessDNA methylation profiling identifies long-range epigenetic silencing of clustered protocadherins as a key determinant of meningioma progression
Meningioma is the most common primary brain tumour in adults. However, molecular drivers of progression occurring in a subset of meningiomas are poorly understood. We hypothesise that epigenomic variations are causal for the clinical heterogeneity of meningiomas and may be functionally relevant for disease progression. To test this hypothesis, we perform global DNA methylation profiling of a large cross-sectional cohort and a longitudinal cohort of human meningiomas. Our analysis identifies a DNA hypermethylation signature that is correlated with clinical outcomes and enables more accurate prognostication for meningiomas than previous classification systems. Analyses of longitudinal high-grade meningioma samples in comparison to clinically benign meningiomas and normal meningeal tissue show convergent contributions but differing plasticity of copy number variations and DNA hypermethylation along the trajectory of meningioma progression. Systematic analysis of DNA hypermethylation in high-grade meningiomas unravels a tumour suppressive role of clustered protocadherins by restricting β-catenin nuclear localisation, consistent with the association between nuclear β-catenin staining and meningioma progression. Together, our study provides fundamental insights into the molecular mechanisms underlying the heterogeneity of clinically benign and aggressive meningiomas and the microevolutionary adaptation during disease progression.
- Open Access
- 11 March 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (18) , e04889
Mapping the Cerebral Organoid Landscape: A Systematic Review of Preclinical 3D Models in Neuroscience
Cerebral organoids are complex, three‐dimensional (3D) dynamic models that recapitulate key features of brain development and disease. These systems serve as bioengineerable platforms with diverse architectures and customizable properties, enabling advances in both basic and translational neuroscience. Despite rapid adoption across neurodevelopment, neurodegeneration, and neuro‐oncology, the field remains fragmented, with substantial methodological variability and no standardized framework for model selection. A systematic review of 738 original studies published between 2014 and 2024, drawn from 3631 articles across PubMed, Semantic Scholar, and OpenAlex, reveals that human induced pluripotent stem cell‐derived cerebral organoids and neurodevelopmental studies dominate the field. In contrast, applications in neurodegeneration, brain metastases, and non‐human systems remain limited, narrowing the translational scope. To address the challenge of navigating this expanding literature, OrganoidMap is introduced—an open‐access, interactive web platform for exploring, filtering, and comparing cerebral organoid models across disease areas, cell sources, and methodological features. OrganoidMap enables the identification of appropriate models for specific experimental goals and reveals underexplored research areas. This synthesis establishes a scalable foundation for enhancing transparency, reproducibility, and model selection in organoid‐based research, setting a new benchmark for how neuroscience and biomaterials communities organize, share, and advance cerebral organoid science.
- 11 March 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (18) , e04889
Open AccessMapping the Cerebral Organoid Landscape: A Systematic Review of Preclinical 3D Models in Neuroscience
Cerebral organoids are complex, three‐dimensional (3D) dynamic models that recapitulate key features of brain development and disease. These systems serve as bioengineerable platforms with diverse architectures and customizable properties, enabling advances in both basic and translational neuroscience. Despite rapid adoption across neurodevelopment, neurodegeneration, and neuro‐oncology, the field remains fragmented, with substantial methodological variability and no standardized framework for model selection. A systematic review of 738 original studies published between 2014 and 2024, drawn from 3631 articles across PubMed, Semantic Scholar, and OpenAlex, reveals that human induced pluripotent stem cell‐derived cerebral organoids and neurodevelopmental studies dominate the field. In contrast, applications in neurodegeneration, brain metastases, and non‐human systems remain limited, narrowing the translational scope. To address the challenge of navigating this expanding literature, OrganoidMap is introduced—an open‐access, interactive web platform for exploring, filtering, and comparing cerebral organoid models across disease areas, cell sources, and methodological features. OrganoidMap enables the identification of appropriate models for specific experimental goals and reveals underexplored research areas. This synthesis establishes a scalable foundation for enhancing transparency, reproducibility, and model selection in organoid‐based research, setting a new benchmark for how neuroscience and biomaterials communities organize, share, and advance cerebral organoid science.
- 11 September 2024
- Published by Springer Nature in Nature
- Vol. 633 (8031) , 777-778
Lipid recycling by macrophage cells drives the growth of brain cancer
- 11 September 2024
- Published by Springer Nature in Nature
- Vol. 633 (8031) , 777-778
Lipid recycling by macrophage cells drives the growth of brain cancer
- 21 September 2023
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 25 (12) , 2302-2304
Towards more Diversity in Neuro-oncology Leadership—the DivINe Initiative
- 21 September 2023
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 25 (12) , 2302-2304
Towards more Diversity in Neuro-oncology Leadership—the DivINe Initiative
- Open Access
- 13 June 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (12) , 10055
The Brain Pre-Metastatic Niche: Biological and Technical Advancements
Metastasis, particularly brain metastasis, continues to puzzle researchers to this day, and exploring its molecular basis promises to break ground in developing new strategies for combatting this deadly cancer. In recent years, the research focus has shifted toward the earliest steps in the formation of metastasis. In this regard, significant progress has been achieved in understanding how the primary tumor affects distant organ sites before the arrival of tumor cells. The term pre-metastatic niche was introduced for this concept and encompasses all influences on sites of future metastases, ranging from immunological modulation and ECM remodeling to the softening of the blood–brain barrier. The mechanisms governing the spread of metastasis to the brain remain elusive. However, we begin to understand these processes by looking at the earliest steps in the formation of metastasis. This review aims to present recent findings on the brain pre-metastatic niche and to discuss existing and emerging methods to further explore the field. We begin by giving an overview of the pre-metastatic and metastatic niches in general before focusing on their manifestations in the brain. To conclude, we reflect on the methods usually employed in this field of research and discuss novel approaches in imaging and sequencing.
- 13 June 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (12) , 10055
Open AccessThe Brain Pre-Metastatic Niche: Biological and Technical Advancements
Metastasis, particularly brain metastasis, continues to puzzle researchers to this day, and exploring its molecular basis promises to break ground in developing new strategies for combatting this deadly cancer. In recent years, the research focus has shifted toward the earliest steps in the formation of metastasis. In this regard, significant progress has been achieved in understanding how the primary tumor affects distant organ sites before the arrival of tumor cells. The term pre-metastatic niche was introduced for this concept and encompasses all influences on sites of future metastases, ranging from immunological modulation and ECM remodeling to the softening of the blood–brain barrier. The mechanisms governing the spread of metastasis to the brain remain elusive. However, we begin to understand these processes by looking at the earliest steps in the formation of metastasis. This review aims to present recent findings on the brain pre-metastatic niche and to discuss existing and emerging methods to further explore the field. We begin by giving an overview of the pre-metastatic and metastatic niches in general before focusing on their manifestations in the brain. To conclude, we reflect on the methods usually employed in this field of research and discuss novel approaches in imaging and sequencing.
- Open Access
Decoding Single Cell Morphology in Osteotropic Breast Cancer Cells for Dissecting Their Migratory, Molecular and Biophysical Heterogeneity
Breast cancer is a heterogeneous disease and the mechanistic framework for differential osteotropism among intrinsic breast cancer subtypes is unknown. Hypothesizing that cell morphology could be an integrated readout for the functional state of a cancer cell, we established a catalogue of the migratory, molecular and biophysical traits of MDA-MB-231 breast cancer cells, compared it with two enhanced bone-seeking derivative cell lines and integrated these findings with single cell morphology profiles. Such knowledge could be essential for predicting metastatic capacities in breast cancer. High-resolution microscopy revealed a heterogeneous and specific spectrum of single cell morphologies in bone-seeking cells, which correlated with differential migration and stiffness. While parental MDA-MB-231 cells showed long and dynamic membrane protrusions and were enriched in motile cells with continuous and mesenchymal cell migration, bone-seeking cells appeared with discontinuous mesenchymal or amoeboid-like migration. Although non-responsive to CXCL12, bone-seeking cells responded to epidermal growth factor with a morphotype shift and differential expression of genes controlling cell shape and directional migration. Hence, single cell morphology encodes the molecular, migratory and biophysical architecture of breast cancer cells and is specifically altered among osteotropic phenotypes. Quantitative morpho-profiling could aid in dissecting breast cancer heterogeneity and in refining clinically relevant intrinsic breast cancer subtypes.
Open AccessDecoding Single Cell Morphology in Osteotropic Breast Cancer Cells for Dissecting Their Migratory, Molecular and Biophysical Heterogeneity
Breast cancer is a heterogeneous disease and the mechanistic framework for differential osteotropism among intrinsic breast cancer subtypes is unknown. Hypothesizing that cell morphology could be an integrated readout for the functional state of a cancer cell, we established a catalogue of the migratory, molecular and biophysical traits of MDA-MB-231 breast cancer cells, compared it with two enhanced bone-seeking derivative cell lines and integrated these findings with single cell morphology profiles. Such knowledge could be essential for predicting metastatic capacities in breast cancer. High-resolution microscopy revealed a heterogeneous and specific spectrum of single cell morphologies in bone-seeking cells, which correlated with differential migration and stiffness. While parental MDA-MB-231 cells showed long and dynamic membrane protrusions and were enriched in motile cells with continuous and mesenchymal cell migration, bone-seeking cells appeared with discontinuous mesenchymal or amoeboid-like migration. Although non-responsive to CXCL12, bone-seeking cells responded to epidermal growth factor with a morphotype shift and differential expression of genes controlling cell shape and directional migration. Hence, single cell morphology encodes the molecular, migratory and biophysical architecture of breast cancer cells and is specifically altered among osteotropic phenotypes. Quantitative morpho-profiling could aid in dissecting breast cancer heterogeneity and in refining clinically relevant intrinsic breast cancer subtypes.
- 18 October 2021
- Published by Springer Nature in Nature Cancer
- Vol. 2 (10) , 1086-1101
Compensatory CSF2-driven macrophage activation promotes adaptive resistance to CSF1R inhibition in breast-to-brain metastasis
Tumor microenvironment-targeted therapies are emerging as promising treatment options for different cancer types. Tumor-associated macrophages and microglia (TAMs) represent an abundant nonmalignant cell type in brain metastases and have been proposed to modulate metastatic colonization and outgrowth. Here we demonstrate that targeting TAMs at distinct stages of the metastatic cascade using an inhibitor of colony-stimulating factor 1 receptor (CSF1R), BLZ945, in murine breast-to-brain metastasis models leads to antitumor responses in prevention and intervention preclinical trials. However, in established brain metastases, compensatory CSF2Rb–STAT5-mediated pro-inflammatory TAM activation blunted the ultimate efficacy of CSF1R inhibition by inducing neuroinflammation gene signatures in association with wound repair responses that fostered tumor recurrence. Consequently, blockade of CSF1R combined with inhibition of STAT5 signaling via AC4-130 led to sustained tumor control, a normalization of microglial activation states and amelioration of neuronal damage.
- 18 October 2021
- Published by Springer Nature in Nature Cancer
- Vol. 2 (10) , 1086-1101
Compensatory CSF2-driven macrophage activation promotes adaptive resistance to CSF1R inhibition in breast-to-brain metastasis
Tumor microenvironment-targeted therapies are emerging as promising treatment options for different cancer types. Tumor-associated macrophages and microglia (TAMs) represent an abundant nonmalignant cell type in brain metastases and have been proposed to modulate metastatic colonization and outgrowth. Here we demonstrate that targeting TAMs at distinct stages of the metastatic cascade using an inhibitor of colony-stimulating factor 1 receptor (CSF1R), BLZ945, in murine breast-to-brain metastasis models leads to antitumor responses in prevention and intervention preclinical trials. However, in established brain metastases, compensatory CSF2Rb–STAT5-mediated pro-inflammatory TAM activation blunted the ultimate efficacy of CSF1R inhibition by inducing neuroinflammation gene signatures in association with wound repair responses that fostered tumor recurrence. Consequently, blockade of CSF1R combined with inhibition of STAT5 signaling via AC4-130 led to sustained tumor control, a normalization of microglial activation states and amelioration of neuronal damage.
- 16 October 2021
- Published by Springer Nature
- p. 11-38
Activation of Microglia and Macrophages in Neurodegenerative Diseases
- 16 October 2021
- Published by Springer Nature
- p. 11-38
Activation of Microglia and Macrophages in Neurodegenerative Diseases